US Type I borosilicate glass vials for injectables & infusions are seeing increased demand across India, driven by US FDA approved formulation facilities in the country. There are now over 169 US FDA facilities in India, all of which need to adhere to international regulatory norms which call for specific glass pack requirements in packaging. This has increased sales of high value & the injectable market is expected to rise in India, judging by the increasing number of US FDA approved facilities. However, currently glass producers manufacturing amber glass are bogged down by excess capacity & volatile currency rates. Customarily oral dosage forms are packed in amber glass, but there has been a shift towards PET packaging. Fortunately for the manufacturers, the amber capacity is interchangeable & glassmakers can switch to other bottle production.
